JP2018513668A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513668A5
JP2018513668A5 JP2017534286A JP2017534286A JP2018513668A5 JP 2018513668 A5 JP2018513668 A5 JP 2018513668A5 JP 2017534286 A JP2017534286 A JP 2017534286A JP 2017534286 A JP2017534286 A JP 2017534286A JP 2018513668 A5 JP2018513668 A5 JP 2018513668A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
molecule
acid molecule
strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017534286A
Other languages
English (en)
Japanese (ja)
Other versions
JP6793649B2 (ja
JP2018513668A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/067556 external-priority patent/WO2016106401A2/en
Publication of JP2018513668A publication Critical patent/JP2018513668A/ja
Publication of JP2018513668A5 publication Critical patent/JP2018513668A5/ja
Application granted granted Critical
Publication of JP6793649B2 publication Critical patent/JP6793649B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017534286A 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ剤 Active JP6793649B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2014266198 2014-12-26
JP2014266198 2014-12-26
US201562184209P 2015-06-24 2015-06-24
US62/184,209 2015-06-24
US201562266668P 2015-12-13 2015-12-13
US62/266,668 2015-12-13
PCT/US2015/067556 WO2016106401A2 (en) 2014-12-26 2015-12-28 Rna agents for p21 gene modulation

Publications (3)

Publication Number Publication Date
JP2018513668A JP2018513668A (ja) 2018-05-31
JP2018513668A5 true JP2018513668A5 (cg-RX-API-DMAC7.html) 2019-02-14
JP6793649B2 JP6793649B2 (ja) 2020-12-02

Family

ID=56151549

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2017534294A Active JP6730285B2 (ja) 2014-12-26 2015-12-28 Ｒｎａ干渉組成物及び悪性腫瘍のための方法
JP2017534275A Pending JP2018512373A (ja) 2014-12-26 2015-12-28 Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物
JP2017534274A Pending JP2018513104A (ja) 2014-12-26 2015-12-28 Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法
JP2017534286A Active JP6793649B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ剤
JP2017534287A Pending JP2018513669A (ja) 2014-12-26 2015-12-28 Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤
JP2017534297A Active JP6457645B2 (ja) 2014-12-26 2015-12-28 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
JP2017534279A Active JP6865169B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ干渉剤
JP2021183788A Active JP7307137B2 (ja) 2014-12-26 2021-11-11 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2023106970A Active JP7655971B2 (ja) 2014-12-26 2023-06-29 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2025046972A Pending JP2025102833A (ja) 2014-12-26 2025-03-21 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2017534294A Active JP6730285B2 (ja) 2014-12-26 2015-12-28 Ｒｎａ干渉組成物及び悪性腫瘍のための方法
JP2017534275A Pending JP2018512373A (ja) 2014-12-26 2015-12-28 Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物
JP2017534274A Pending JP2018513104A (ja) 2014-12-26 2015-12-28 Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2017534287A Pending JP2018513669A (ja) 2014-12-26 2015-12-28 Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤
JP2017534297A Active JP6457645B2 (ja) 2014-12-26 2015-12-28 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
JP2017534279A Active JP6865169B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ干渉剤
JP2021183788A Active JP7307137B2 (ja) 2014-12-26 2021-11-11 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2023106970A Active JP7655971B2 (ja) 2014-12-26 2023-06-29 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2025046972A Pending JP2025102833A (ja) 2014-12-26 2025-03-21 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤

Country Status (10)

Country Link
US (14) US10264976B2 (cg-RX-API-DMAC7.html)
EP (9) EP3683309A1 (cg-RX-API-DMAC7.html)
JP (10) JP6730285B2 (cg-RX-API-DMAC7.html)
KR (4) KR20170096199A (cg-RX-API-DMAC7.html)
CN (7) CN107106591B (cg-RX-API-DMAC7.html)
AU (4) AU2015369592B2 (cg-RX-API-DMAC7.html)
BR (2) BR112017013597B1 (cg-RX-API-DMAC7.html)
CA (4) CA2972270A1 (cg-RX-API-DMAC7.html)
RU (4) RU2017126598A (cg-RX-API-DMAC7.html)
WO (7) WO2016106403A2 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
ES2789049T3 (es) * 2014-12-26 2020-10-23 Nitto Denko Corp Agentes de interferencia de ARN para modulación génica de GST-pi
US11045488B2 (en) * 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US20180002702A1 (en) * 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10167253B2 (en) * 2015-06-24 2019-01-01 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
JP6457704B2 (ja) 2015-12-13 2019-01-23 日東電工株式会社 高活性及びオフターゲット削減のためのｓｉＲＮＡ構造
CN109477146B (zh) 2016-05-10 2023-09-19 国立大学法人东京医科齿科大学 炎症促进因子表达抑制剂、其有效成分的筛选方法、对该方法有用的表达盒、诊断药和诊断方法
WO2018151840A2 (en) * 2017-02-16 2018-08-23 Nitto Denko Corporation Methods and compositions for treating malignant tumors
BR112020008451A2 (pt) 2017-11-06 2020-12-01 Nitto Denko Corporation composto fusogênico, composição, composições farmacêutica e para uso na distribuição de um agente ativo, e, método para prevenir, melhorar ou tratar uma doença ou condição
TWI816712B (zh) * 2017-11-09 2023-10-01 國立大學法人東京醫科齒科大學 癌促進因子表現抑制劑的有效成分之篩選用試藥及其篩選方法、癌之預防或治療劑的有效成分之篩選用試藥及其篩選方法、癌促進因子表現抑制劑及癌之預防或治療劑
CN109777798A (zh) * 2017-11-13 2019-05-21 深圳华大生命科学研究院 一种基于CRISPR技术治疗KRAS突变恶性肿瘤的sgRNA及其应用
JP6952594B2 (ja) * 2017-12-15 2021-10-20 洋司郎 新津 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
CN108486011B (zh) * 2018-03-27 2020-05-05 山东大学 一种三联苯化合物、制备方法及其应用
JP7432929B2 (ja) * 2018-05-31 2024-02-19 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途
WO2020009189A1 (ja) * 2018-07-05 2020-01-09 洋司郎 新津 Ｂｒａｆ阻害剤によるがん細胞の逆説的増殖を抑制する薬剤
EP3848050A4 (en) * 2018-08-22 2022-06-08 Nitto Denko Corporation DRUG USING AN HSP47 INHIBITOR TO INCREASE SENSITIVITY TO A CHEMOTHERAPY DRUG
CN112739381A (zh) * 2018-08-22 2021-04-30 日东电工株式会社 使用了hsp47的抑制物质的癌转移抑制
WO2020102668A1 (en) * 2018-11-16 2020-05-22 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
US20220016156A1 (en) * 2018-12-05 2022-01-20 Nitto Denko Corporation Rnai molecule for treating cancer
US20220202846A1 (en) 2019-01-10 2022-06-30 Osaka University Immunostimulating composition
WO2020196736A1 (ja) * 2019-03-28 2020-10-01 日東電工株式会社 ＲＮＡｉ分子
JP2019116507A (ja) * 2019-04-25 2019-07-18 有限会社オービット Ｈｓｐ４７の発現促進剤、脱毛抑制方法、Ｈｓｐ４７の発現促進剤の製造方法及び飲食物の製造方法
WO2021001646A2 (en) * 2019-07-02 2021-01-07 Argonaute RNA Limited Apolipoprotein b antagonist
EP4005602A4 (en) * 2019-07-30 2024-06-12 Shionogi & Co., Ltd NUCLEIC ACID AGENT TARGETED AGAINST MURF1
WO2021146548A1 (en) * 2020-01-17 2021-07-22 Anastasia Khvorova Universal dynamic pharmacokinetic-modifying anchors
CN112280800B (zh) * 2020-10-19 2022-06-07 上海市东方医院（同济大学附属东方医院） 一种构建体及其在制备动物衰老细胞示踪和衰老细胞清除药物中的应用
AU2021416356A1 (en) 2020-12-28 2023-08-10 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
WO2022144882A2 (en) * 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna target areas for silencing
KR102732912B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732913B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732909B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732910B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732911B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
EP4516905A1 (en) * 2022-04-27 2025-03-05 Kyoto University Epicardial cell regeneration promoter and method for promoting epicardial cell regeneration
WO2025072649A1 (en) * 2023-09-28 2025-04-03 Nitto Denko Corporation Combination therapy

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339303C (en) 1987-09-21 1997-08-19 Lyle John Arnold Jr. Non-nucleotide linking reagents for nucleotide probes
US5204241A (en) 1990-10-22 1993-04-20 Oxi-Gene Inc. Glutathione-S-transferase mu as a measure of drug resistance
US5786336A (en) 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
PT748382E (pt) 1993-09-02 2003-03-31 Ribozyme Pharm Inc Acidos nucleicos enzimaticos contendo nao-nucleotidos
AU8088694A (en) 1993-10-27 1995-05-22 Ribozyme Pharmaceuticals, Inc. 2'-amido and 2'-peptido modified oligonucleotides
JPH11507056A (ja) 1995-06-07 1999-06-22 テラピン テクノロジーズ、インク． グルタチオンアナログの代謝的効果
US5968737A (en) 1996-11-12 1999-10-19 The University Of Mississippi Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
JPH10330249A (ja) * 1997-05-30 1998-12-15 Kureha Chem Ind Co Ltd レチノール化合物含有ｈｓｐ４７合成抑制剤
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU766515B2 (en) 1998-04-16 2003-10-16 Teijin Limited Glutathione derivatives and dosage forms thereof
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20070083945A1 (en) 2000-03-10 2007-04-12 Byrum Joseph R Nucleic acid molecules and other molecules associated with plants
WO2001088191A1 (en) * 2000-03-29 2001-11-22 The United States Of America As Represented By The Department Of Veterans Affairs A novel specific inhibitor of the cyclin kinase inhibitor p21?waf1/cip1¿
JP2004508019A (ja) * 2000-07-28 2004-03-18 コンピュジェン　インコーポレイテッド トランスクリプトームの中に場所を占めるｒｎａ転写物及びスプライス変異体を検出するためのオリゴヌクレオチドライブラリー
CZ308053B6 (cs) 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
AU2004266311B2 (en) * 2001-05-18 2009-07-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US20040219600A1 (en) 2002-12-13 2004-11-04 Williams Robert Wood Method for determining sensitivity to environmental toxins and susceptibility to parkinson's disease
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050142596A1 (en) 2003-11-14 2005-06-30 Krolewski Andrzej S. Methods of diagnosing renal and cardiovascular disease
US20050277610A1 (en) 2004-03-15 2005-12-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
IL179285A (en) * 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
MX2007002294A (es) 2004-08-26 2007-10-19 Engeneic Molecular Delivery Pty Ltd Suministro de acidos nucleicos funcionales a celulas mamiferas via minicelulas intactas, derivadas bacterialmente.
WO2006068232A1 (ja) 2004-12-22 2006-06-29 Sapporo Medical University 線維化抑制のための薬物担体および薬物担体キット
US9393315B2 (en) * 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
EP1874793A4 (en) 2005-04-15 2008-12-24 Univ Texas DISTRIBUTION OF SIRNA BY NEUTRAL LIPID COMPOSITIONS
WO2007072220A2 (en) * 2005-09-12 2007-06-28 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
ES2324128A1 (es) 2005-09-29 2009-07-30 Proyecto De Biomedicina Cima, S.L. Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares.
EP1954820A1 (en) 2005-10-25 2008-08-13 Het Nederlands Kanker Instituut Prediction of local recurrence of breast cancer
EP2202239A1 (en) 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAI inhibition of influenza virus replication
RU2448974C2 (ru) * 2005-11-01 2012-04-27 Элнилэм Фармасьютикалз, Инк. РНКи-ИНГИБИРОВАНИЕ РЕПЛИКАЦИИ ВИРУСА ГРИППА
CA2628300C (en) 2005-11-02 2018-04-17 Protiva Biotherapeutics, Inc. Modified sirna molecules and uses thereof
EP1948213B1 (en) * 2005-11-17 2009-02-04 The Children's Medical Center Corporation Methods to predict and prevent resistance to taxoid compounds
US7729737B2 (en) 2005-11-22 2010-06-01 Isense Corporation Method and apparatus for background current arrangements for a biosensor
CA2631677C (en) 2005-12-01 2014-08-12 Pronai Therapeutics, Inc. Amphoteric liposome formulation
US9572886B2 (en) * 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US20070258952A1 (en) * 2006-05-04 2007-11-08 Baylor Research Institute Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
EA015676B1 (ru) 2006-05-11 2011-10-31 Элнилэм Фармасьютикалз, Инк. Композиции и способы ингибирования экспрессии гена pcsk9
WO2008109432A2 (en) 2007-03-02 2008-09-12 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using sirna in neutral liposomes
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
AU2008270209B2 (en) 2007-07-05 2012-05-17 Arrowhead Pharmaceuticals, Inc. dsRNA for treating viral infection
DK2193140T3 (en) * 2007-08-27 2017-01-23 Iglobe Health Inst Llc COMPOSITIONS OF ASYMMETRIC INTERFERRING RNA AND ITS APPLICATIONS
WO2009033284A1 (en) 2007-09-14 2009-03-19 Mcmaster University Inhibitors of collagen biosynthesis as anti-tumor agents
EP2268628B1 (en) * 2008-03-06 2012-05-16 Rottapharm S.p.A. 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain
JP2011528910A (ja) 2008-07-25 2011-12-01 アルニラム ファーマスーティカルズ インコーポレイテッド センス鎖中の一般塩基またはミスマッチを使用したｓｉＲＮＡサイレンシング活性の亢進
CA2732412C (en) * 2008-07-30 2014-12-09 Lei Yu Retinoid-targeted drug carriers
CA2816925C (en) * 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
US8710209B2 (en) * 2009-12-09 2014-04-29 Nitto Denko Corporation Modulation of HSP47 expression
AU2011220749B2 (en) 2010-02-24 2017-02-02 Bodysync, Inc. Methods for determining gene-nutrient interactions
US20130004494A1 (en) * 2010-03-12 2013-01-03 Ellen Heber-Katz Inhibition of P21 and Use Thereof for Inducing Tissue Regeneration
US8372819B2 (en) * 2010-04-11 2013-02-12 Salk Institute For Biological Studies Methods and compositions for targeting skip
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
CN103025865A (zh) 2010-05-06 2013-04-03 干细胞医药有限公司 用于个性化医疗的干细胞库
JP5950428B2 (ja) * 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
RU2013107129A (ru) 2010-09-30 2014-11-10 Нитто Денко Корпорейшн Модуляция экспрессии timp1 и timp2
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
KR102038300B1 (ko) 2011-06-08 2019-10-31 닛토덴코 가부시키가이샤 표적 약물 전달체 및 ｓｉＲＮＡ 활성을 증가시키는 화합물
TWI658830B (zh) * 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US9011903B2 (en) * 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
US20140315975A1 (en) * 2011-06-21 2014-10-23 Nitto Denko Corporation Apoptosis-inducing agent
CN102896619B (zh) * 2011-07-26 2015-04-22 苏州宝时得电动工具有限公司 动力工具及其操作方法
CA2846074A1 (en) * 2011-08-31 2013-05-10 Alexzander A. Asea Compositions and methods for treatment of metastatic cancer
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
WO2013075140A1 (en) * 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Auto -recognizing therapeutic rna/dna chimeric nanoparticles (np)
HK1208361A1 (en) * 2012-05-16 2016-03-04 Aadigen, Llc Multi-target modulation for treating fibrosis and inflammatory conditions
US20140134158A1 (en) 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
TWI654997B (zh) 2012-06-08 2019-04-01 日商日東電工股份有限公司 用於治療劑輸送配方之脂質
WO2013192364A1 (en) 2012-06-22 2013-12-27 The University Of Vermont And State Agricultural College Treatments of oxidative stress conditions
EP2866835A1 (en) * 2012-07-02 2015-05-06 Fibrostatin, S.L. Gpbp-1 inhibition and its therapeutic use
EP2880162B1 (en) 2012-08-03 2017-07-05 Alnylam Pharmaceuticals, Inc. Modified rnai agents
JP6340162B2 (ja) * 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6352950B2 (ja) 2013-03-08 2018-07-04 ノバルティス アーゲー 活性薬物の送達のための脂質と脂質組成物
CN103695421B (zh) * 2013-12-09 2016-06-15 浙江大学 一种特异抑制p21基因表达的siRNA及其应用
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US20160187319A1 (en) 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10792299B2 (en) * 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
WO2016104588A1 (ja) * 2014-12-26 2016-06-30 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物
JP6457704B2 (ja) * 2015-12-13 2019-01-23 日東電工株式会社 高活性及びオフターゲット削減のためのｓｉＲＮＡ構造
JP6899201B2 (ja) 2016-06-23 2021-07-07 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物

Similar Documents

Publication Publication Date Title
JP2018513668A5 (cg-RX-API-DMAC7.html)
Grimm Small silencing RNAs: state-of-the-art
Azlan et al. Argonaute: The executor of small RNA function
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
EP4455285A3 (en) Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
JP2017079776A5 (cg-RX-API-DMAC7.html)
JP2018512041A5 (cg-RX-API-DMAC7.html)
JP2014527401A5 (cg-RX-API-DMAC7.html)
JP2018512110A5 (cg-RX-API-DMAC7.html)
Goodchild Therapeutic oligonucleotides
HK1221978A1 (zh) Tmprss6 irna组合物及其使用方法
HRP20201200T1 (hr) OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK
WO2009078685A3 (en) Novel sirna structure for minimizing off-target effects and relaxing saturation of rnai machinery and the use thereof
JP2017093448A5 (cg-RX-API-DMAC7.html)
JP2013532952A5 (cg-RX-API-DMAC7.html)
EP4527459A3 (en) Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
CN110944675A (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP2015518721A5 (cg-RX-API-DMAC7.html)
JP2013226147A5 (cg-RX-API-DMAC7.html)
WO2013192576A3 (en) Oligonucleotide-based inhibitors comprising locked nucleic acid motif
JP2010057515A5 (cg-RX-API-DMAC7.html)
RU2016129053A (ru) Нуклеиновые кислоты, индуцирующие рнк-интерференцию, модифицированные для предотвращения побочных эффектов, и их применение
JP2015142558A5 (cg-RX-API-DMAC7.html)
JP2015523855A5 (cg-RX-API-DMAC7.html)
JP2012223202A5 (cg-RX-API-DMAC7.html)